ArticleOpen life sciences2021
Two new inflammatory markers related to the CURB-65 score for disease severity in patients with community-acquired pneumonia: The hypersensitive C-reactive protein to albumin ratio and fibrinogen to albumin ratio.
Article in Open life sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Admission fibrinogen-to-albumin ratio and mortality in older adults hospitalized with pneumonia: a retrospective cohort study.BMC infectious diseases · 2026Article
- The Diagnostic and Prognostic Value of Procalcitonin and High-Sensitivity C-Reactive Protein in Early-Stage Burn Sepsis: A Retrospective Cohort Study.Journal of inflammation research · 2026Article
- Inflammatory indices are associated with non-suicidal self-injury in adolescents with major depressive disorder.BMC psychiatry · 2025Article
- Advancing ICU mortality prediction in community-acquired pneumonia: Combining fibrinogen-to-albumin ratio, CT severity score, PSI, and CURB-65.Biomolecules & biomedicine · 2025Article
- The C-reactive protein-to-albumin ratio as a diagnostic biomarker for rheumatoid arthritis: a cross-sectional NHANES analysis.Frontiers in medicine · 2025Article
- A prediction model for hospital mortality in patients with severe community-acquired pneumonia and chronic obstructive pulmonary disease.Respiratory research · 2022Observational
- C-Reactive Protein-to-Albumin Ratio and Clinical Outcomes in COVID-19 Patients: A Systematic Review and Meta-Analysis.Tropical medicine and infectious disease · 2022Review
- Fibrinogen-to-Albumin Ratio and Blood Urea Nitrogen-to-Albumin Ratio in COVID-19 Patients: A Systematic Review and Meta-Analysis.Tropical medicine and infectious disease · 2022Review
- Clinical and prognostic significance of C-reactive protein to albumin ratio in hospitalized coronavirus disease 2019 (COVID-19) patients : Data on 2309 patients from a tertiary center and validation in an independent cohort.Wiener klinische Wochenschrift · 2022Article
- Use of Routine Hematological and Biochemical Parameters to Predict Clinical Outcomes in Community-acquired Pneumonia.Saudi journal of medicine & medical sciencesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe objective of this study was to investigate the relationship among hypersensitive C-reactive protein to albumin ratio (CAR), fibrinogen to albumin ratio (FAR), and the CURB-65 score for community-acquired pneumonia (CAP) severity.
methodsClinical data and laboratory indicators of 82 patients with CAP and 40 healthy subjects were retrospectively analysed. The relationship among CAR, FAR, and the severity of CAP was then analysed.
resultsCAR and FAR in patients with low-risk CAP were significantly higher than those in the normal control group (
conclusionsCAR and FAR may be used as the inflammatory markers for CAP severity evaluation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.